» Articles » PMID: 19668339

Hippocampal Atrophy As a Quantitative Trait in a Genome-wide Association Study Identifying Novel Susceptibility Genes for Alzheimer's Disease

Overview
Journal PLoS One
Date 2009 Aug 12
PMID 19668339
Citations 216
Authors
Affiliations
Soon will be listed here.
Abstract

Background: With the exception of APOE epsilon4 allele, the common genetic risk factors for sporadic Alzheimer's Disease (AD) are unknown.

Methods And Findings: We completed a genome-wide association study on 381 participants in the ADNI (Alzheimer's Disease Neuroimaging Initiative) study. Samples were genotyped using the Illumina Human610-Quad BeadChip. 516,645 unique Single Nucleotide Polymorphisms (SNPs) were included in the analysis following quality control measures. The genotype data and raw genetic data are freely available for download (LONI, http://www.loni.ucla.edu/ADNI/Data/). Two analyses were completed: a standard case-control analysis, and a novel approach using hippocampal atrophy measured on MRI as an objectively defined, quantitative phenotype. A General Linear Model was applied to identify SNPs for which there was an interaction between the genotype and diagnosis on the quantitative trait. The case-control analysis identified APOE and a new risk gene, TOMM40 (translocase of outer mitochondrial membrane 40), at a genome-wide significance level of < or =10(-6) (10(-11) for a haplotype). TOMM40 risk alleles were approximately twice as frequent in AD subjects as controls. The quantitative trait analysis identified 21 genes or chromosomal areas with at least one SNP with a p-value < or =10(-6), which can be considered potential "new" candidate loci to explore in the etiology of sporadic AD. These candidates included EFNA5, CAND1, MAGI2, ARSB, and PRUNE2, genes involved in the regulation of protein degradation, apoptosis, neuronal loss and neurodevelopment. Thus, we identified common genetic variants associated with the increased risk of developing AD in the ADNI cohort, and present publicly available genome-wide data. Supportive evidence based on case-control studies and biological plausibility by gene annotation is provided. Currently no available sample with both imaging and genetic data is available for replication.

Conclusions: Using hippocampal atrophy as a quantitative phenotype in a genome-wide scan, we have identified candidate risk genes for sporadic Alzheimer's disease that merit further investigation.

Citing Articles

The global research of magnetic resonance imaging in Alzheimer's disease: a bibliometric analysis from 2004 to 2023.

Sun X, Zhu J, Li R, Peng Y, Gong L Front Neurol. 2025; 15:1510522.

PMID: 39882364 PMC: 11774745. DOI: 10.3389/fneur.2024.1510522.


TOMM40 may mediate GFAP, neurofilament light Protein, pTau181, and brain morphometry in aging.

Honea R, Wilkins H, Hunt S, Kueck P, Burns J, Swerdlow R Aging Brain. 2025; 7:100134.

PMID: 39760103 PMC: 11699468. DOI: 10.1016/j.nbas.2024.100134.


Association of APOE alleles and polygenic profiles comprising APOE-TOMM40-APOC1 variants with Alzheimer's disease neuroimaging markers.

Kulminski A, Jain-Washburn E, Nazarian A, Wilkins H, Veatch O, Swerdlow R Alzheimers Dement. 2024; 21(2):e14445.

PMID: 39713891 PMC: 11848341. DOI: 10.1002/alz.14445.


The effect size of rs521851 in the intron of MAGI2/S-SCAM on HADS-D scores correlates with EAT-26 scores for eating disorders risk.

Pinakhina D, Kasyanov E, Rukavishnikov G, Larin A, Veselovsky V, Rakitko A Front Psychiatry. 2024; 15:1416009.

PMID: 39703455 PMC: 11656592. DOI: 10.3389/fpsyt.2024.1416009.


Alterations of the IKZF1-IKZF2 tandem in immune cells of schizophrenia patients regulate associated phenotypes.

Ballasch I, Lopez-Molina L, Galan-Ganga M, Sancho-Balsells A, Rodriguez-Navarro I, Borras-Pernas S J Neuroinflammation. 2024; 21(1):326.

PMID: 39695786 PMC: 11658472. DOI: 10.1186/s12974-024-03320-3.


References
1.
Cherbuin N, Anstey K, Sachdev P, Maller J, Meslin C, Mack H . Total and regional gray matter volume is not related to APOE*E4 status in a community sample of middle-aged individuals. J Gerontol A Biol Sci Med Sci. 2008; 63(5):501-4. DOI: 10.1093/gerona/63.5.501. View

2.
Upadhya S, Hegde A . Role of the ubiquitin proteasome system in Alzheimer's disease. BMC Biochem. 2007; 8 Suppl 1:S12. PMC: 2106363. DOI: 10.1186/1471-2091-8-S1-S12. View

3.
Arvanitis D, Davy A . Eph/ephrin signaling: networks. Genes Dev. 2008; 22(4):416-29. PMC: 2731651. DOI: 10.1101/gad.1630408. View

4.
Blurton-Jones M, LaFerla F . Pathways by which Abeta facilitates tau pathology. Curr Alzheimer Res. 2006; 3(5):437-48. DOI: 10.2174/156720506779025242. View

5.
Reber M, Hindges R, Lemke G . Eph receptors and ephrin ligands in axon guidance. Adv Exp Med Biol. 2008; 621:32-49. DOI: 10.1007/978-0-387-76715-4_3. View